Home > Healthcare > Pharmaceuticals > Finished Drug Form > Complex Regional Pain Syndrome (CRPS) Market

Complex Regional Pain Syndrome (CRPS) Market Trends

Report ID: GMI12148
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Complex Regional Pain Syndrome Market Trends

The rising prevalence of complex regional pain syndrome (CRPS) is a significant growth driver in the CRPS market, driven by an increasing number of surgeries, traumatic injuries, and conditions that can trigger CRPS, such as fractures and soft-tissue injuries. As awareness and diagnostic capabilities for CRPS improve, more cases are identified, expanding the patient base requiring effective treatments. Additionally, aging populations are more susceptible to conditions like CRPS due to higher surgery rates and slower recovery from injuries. This growing patient pool fuels demand for advanced pain management solutions, including neurostimulation devices, pharmaceuticals, and physical therapies tailored to CRPS symptoms and recovery.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for complex regional pain syndrome was valued at approximately USD 109 million in 2023 and is expected to reach around USD 134.2 million by 2032, driven by a CAGR of over 2.4% from 2024 to 2032.

The CRPS Type I segment accounted for USD 91.2 million in 2023, representing nearly 90% of all CRPS cases, driven by its prevalence following injuries or illnesses that do not directly damage the nerves.

U.S. market generated USD 49.8 million by the end of 2032, driven by a high incidence of chronic pain conditions and a strong healthcare infrastructure.

Major players in the industry include Abbott Laboratories, AbbVie, Averitas Pharma, Boston Scientific, Collegium Pharmaceutical, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, and Medtronic.